These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clomipramine (Anafranil) in depressive patients with obsessive neurosis.
    Author: Singh AN, Sexena B, Gent M.
    Journal: J Int Med Res; 1977; 5 Suppl 5():25-32. PubMed ID: 598603.
    Abstract:
    The authors express the view that, clinically, clomipramine (Anafranil, Geigy Pharmaceuticals) seems to be the treatment of choice for obsessive-compulsive illness. Clomipramine possesses a specific anti-obsessional property which is distinct from its antidepressant property. The optimal therapeutic dose from this study appears to be in the range of 175 mg to 225 mg a day. Minor reversible adverse reaction gradually decreases with the increase of duration of treatment.
    [Abstract] [Full Text] [Related] [New Search]